US 8,039,009 B2
Modified release formulations of memantine oral dosage formsGeneral
US 8,039,009 B2
Modified release formulations of memantine oral dosage forms
Tech Center:
1600 Biotechnology and Organic Chemistry
Examiner:
Brandon Fetterolf
Art Unit:
1628 Organic Chemistry
Agent:
Michael Ciraolo, Chareles S. Ryan
Inventors:
Suneel K. Rastogi; Niranjan Rao; Antonia Periclou; Wattanaporn Abramowitz; Mahendra G. Dedhiya; Shashank Mahashabde
Priority:
06/17/04
Filed:
06/16/05
Granted:
10/18/11
Expiration:
03/25/28
Abstract
The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.
Cooperative Patent Classification (CPC)
A61A61K9/2054A61P25/28A61KY02A50/30Y02A